JP2017521074A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521074A5
JP2017521074A5 JP2017500932A JP2017500932A JP2017521074A5 JP 2017521074 A5 JP2017521074 A5 JP 2017521074A5 JP 2017500932 A JP2017500932 A JP 2017500932A JP 2017500932 A JP2017500932 A JP 2017500932A JP 2017521074 A5 JP2017521074 A5 JP 2017521074A5
Authority
JP
Japan
Prior art keywords
variant
bmp9
pharmaceutical composition
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017500932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521074A (ja
JP6737770B2 (ja
Filing date
Publication date
Priority claimed from GBGB1412290.7A external-priority patent/GB201412290D0/en
Application filed filed Critical
Publication of JP2017521074A publication Critical patent/JP2017521074A/ja
Publication of JP2017521074A5 publication Critical patent/JP2017521074A5/ja
Application granted granted Critical
Publication of JP6737770B2 publication Critical patent/JP6737770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017500932A 2014-07-10 2015-07-09 骨形成タンパク質の治療上の使用 Active JP6737770B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1412290.7 2014-07-10
GBGB1412290.7A GB201412290D0 (en) 2014-07-10 2014-07-10 Novel use
PCT/GB2015/051989 WO2016005756A1 (en) 2014-07-10 2015-07-09 Therapeutic use of bone morphogenetic proteins

Publications (3)

Publication Number Publication Date
JP2017521074A JP2017521074A (ja) 2017-08-03
JP2017521074A5 true JP2017521074A5 (OSRAM) 2018-08-23
JP6737770B2 JP6737770B2 (ja) 2020-08-12

Family

ID=51453948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017500932A Active JP6737770B2 (ja) 2014-07-10 2015-07-09 骨形成タンパク質の治療上の使用

Country Status (22)

Country Link
US (4) US10336800B2 (OSRAM)
EP (3) EP3166628B2 (OSRAM)
JP (1) JP6737770B2 (OSRAM)
KR (2) KR20230049757A (OSRAM)
CN (1) CN106661094B (OSRAM)
AU (1) AU2015287397B2 (OSRAM)
CA (1) CA2954221C (OSRAM)
CY (2) CY1123011T1 (OSRAM)
DK (2) DK3166628T3 (OSRAM)
ES (2) ES2770073T5 (OSRAM)
GB (1) GB201412290D0 (OSRAM)
HR (2) HRP20200418T1 (OSRAM)
HU (2) HUE048924T2 (OSRAM)
LT (2) LT3166628T (OSRAM)
MX (2) MX378431B (OSRAM)
PL (2) PL3669886T3 (OSRAM)
PT (2) PT3669886T (OSRAM)
RS (2) RS60181B1 (OSRAM)
RU (1) RU2733318C2 (OSRAM)
SI (2) SI3669886T1 (OSRAM)
SM (2) SMT202100323T1 (OSRAM)
WO (1) WO2016005756A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
CN110603049A (zh) * 2017-02-06 2019-12-20 阿塞勒隆制药公司 用于治疗心力衰竭的组合物和方法
CN111344306A (zh) * 2017-11-02 2020-06-26 拜耳股份公司 结合alk-1和bmpr-2的双特异性抗体
CN107760779B (zh) * 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
WO2019117208A1 (ja) * 2017-12-12 2019-06-20 協和発酵キリン株式会社 抗ｂｍｐ１０抗体及び該抗体を有効成分とする、高血圧および高血圧性疾患に対する治療剤
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物
WO2021113544A1 (en) * 2019-12-03 2021-06-10 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
WO2023012318A1 (en) * 2021-08-05 2023-02-09 Actelion Pharmaceuticals Ltd Bmp9 variant polypeptides and uses thereof
CN114317604B (zh) * 2022-03-04 2022-06-17 中国医学科学院阜外医院 一种自发性肺动脉高压模型及构建方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171355A (en) * 1875-12-21 Improvement in driers
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
JPH09501305A (ja) 1993-05-12 1997-02-10 ジェネティックス・インスティテュート・インコーポレイテッド Ｂｍｐ−１０組成物
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU2947395A (en) 1995-06-06 1996-12-24 Human Genome Sciences, Inc. Bone morphogenic protein-10
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1571159A1 (en) † 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
WO2006130022A1 (en) 2005-05-30 2006-12-07 Agresearch Limited Modulation of ovulation by agonists and antagonists of bmprii
JP2009544325A (ja) 2006-07-27 2009-12-17 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用
BRPI0717964A2 (pt) 2006-11-02 2013-12-17 Acceleron Pharma Inc Receptor e antagonistas de ligante da alk1 e usos dos mesmos.
EP2150560A1 (en) * 2007-06-01 2010-02-10 Wyeth Methods and compositions for modulating bmp-10 activity
CA2718403A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2010114833A1 (en) 2009-04-01 2010-10-07 Indiana University Research And Technology Corporation Methods for treating diseases using a bone morphogenetic protein
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9932386B2 (en) 2011-04-20 2018-04-03 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
RU2748278C2 (ru) * 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
CN107760779B (zh) 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2017521074A5 (OSRAM)
RU2017102381A (ru) Терапевтическое применение костных морфогенетических белков
JP7030894B2 (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体
JP2018537087A5 (OSRAM)
JP2018506286A5 (OSRAM)
JP2018138049A5 (OSRAM)
JP2020506701A5 (OSRAM)
JP2018522563A5 (OSRAM)
JP2018538356A5 (OSRAM)
JP2014512808A5 (OSRAM)
JP2015517489A5 (OSRAM)
JP2017532966A5 (OSRAM)
JP2012115277A5 (OSRAM)
AU2016289492A1 (en) Vaccine against RSV
JP2020023567A5 (OSRAM)
JP2018537089A5 (OSRAM)
JP2020172505A5 (OSRAM)
JP2016513471A5 (OSRAM)
JPWO2019156137A5 (OSRAM)
IL275188B1 (en) Use of cyclic tripeptide to improve cellular energy metabolism
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
JP2020517643A5 (OSRAM)
JP2017527558A5 (OSRAM)
JP2017503505A5 (OSRAM)
JP2019526261A5 (OSRAM)